Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Equity Average (2018 - 2025)

Historic Equity Average for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $32.8 million.

  • X4 Pharmaceuticals' Equity Average fell 5742.9% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year decrease of 5742.9%. This contributed to the annual value of $36.6 million for FY2024, which is 4147.18% down from last year.
  • Latest data reveals that X4 Pharmaceuticals reported Equity Average of $32.8 million as of Q3 2025, which was down 5742.9% from $13.5 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Equity Average high stood at $96.2 million for Q2 2021, and its period low was $13.5 million during Q2 2025.
  • Moreover, its 5-year median value for Equity Average was $59.3 million (2023), whereas its average is $55.3 million.
  • As far as peak fluctuations go, X4 Pharmaceuticals' Equity Average skyrocketed by 4941.16% in 2023, and later tumbled by 7181.29% in 2025.
  • X4 Pharmaceuticals' Equity Average (Quarter) stood at $66.5 million in 2021, then increased by 2.11% to $68.0 million in 2022, then fell by 12.66% to $59.3 million in 2023, then plummeted by 31.11% to $40.9 million in 2024, then decreased by 19.79% to $32.8 million in 2025.
  • Its last three reported values are $32.8 million in Q3 2025, $13.5 million for Q2 2025, and $22.5 million during Q1 2025.